Home Stem Cells & Wnt Hedgehog/Smoothened antagonist PF-5274857

research use only

PF-5274857 Hedgehog/Smoothened antagonist

Cat.No.S2777

PF-5274857 is a potent and selective Smoothened (Smo) antagonist, inhibits Hedgehog (Hh) signaling with IC50 and Ki of 5.8 nM and 4.6 nM, respectively, and this compound can penetrate the blood–brain barrier.
PF-5274857 Hedgehog/Smoothened antagonist Chemical Structure

Chemical Structure

Molecular Weight: 436.96

Jump to

Quality Control

Batch: Purity: 99.86%
99.86

Solubility

In vitro
Batch:

DMSO : 93 mg/mL (212.83 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 93 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 436.96 Formula

C20H25ClN4O3S

 Storage (From the date of receipt)
CAS No. 1373615-35-0 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles CC1=CC(=C(N=C1)C2=CC(=NC=C2Cl)N3CCN(CC3)C(=O)CCS(=O)(=O)C)C

Mechanism of Action

Targets/IC50/Ki
Smoothened
4.6 nM(Ki)
Smoothened
5.8 nM
In vitro
PF-5274857 completely inhibits Shh-induced Hh pathway activity with IC50 of 2.7 nM measured by the transcriptional activity of Smo downstream gene Gli1 in MEF cells. The μ-opioid receptor is weakly inhibited by this compound with a dissociation constant of 36 μM subsequently determined in a functional assay.
Kinase Assay
Biochemical assays
HEK293 cells overexpressing human Smo (amino acids 181-787) are grown in Dulbecco's Modified Eagle's Media (DMEM) supplemented with 10% FBS, Pen–Strep, and 0.1 mg/mL hygromycin to 90% confluence. After washing with cold Dulbecco's PBS, the cell pellet is resuspended in membrane preparation buffer (50 mM Tris-HCl, pH 7.5, 250 mM sucrose with Roche complete protease cocktail) and homogenized. The homogenate is centrifuged and the cell pellet is resuspended in assay buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 25 mM MgCl2, 1 mM EDTA, and 0.1% protease-free bovine serum albumin) and homogenized in a glass tissue grinder. Total protein in the membrane preparation containing Smo is determined using the Pierce BCA protein assay. For the competitive binding assay, 100 μL of assay buffer is added to a 96-well GF/B filter plate for 10 minutes to pre-wet the filter and then removed. The following reagents are then added: 20 μL of assay buffer, 10 μL serial dilutions of this compound, 20 μL of 3H-Smo antagonist (3 nM final concentration), and 50 μL of membrane preparation (40 μg total protein). The plates are incubated at room temperature for 2 hours, then washed and vacuum dried. The plates are then dried for 1 hour in a 60°C oven before the addition of 45 μL of Microscint 20 and incubated at room temperature for 30 minutes to 1 hour, then counted in a TopCount scintillation counter. The data are analyzed using GraphPad Prism software.
In vivo
PF-5274857 shows significant dose-dependent tumor growth inhibition (TGI) and induces tumor regression at high doses(>10 mg/kg)., This compound downregulates Gli1, Gli2, Ptch1, and Ptch2 gene expression levels to various degrees with maximal effects being achieved between 6 and 12 hours post-dose (Gli1 is the most sensitive gene), whereas it has little effect on Smo levels. In skin tissue, downregulation of Gli1 and Gli2 is also observed with a similar time course by this chemical. The model-derived drug concentration for half maximal inhibition of the tumor Gli1 mRNA production rate (IC50) by this compound is determined to be 8.9 nM in the Ptch+/−p53+/− medulloblastoma allograft mice, which mathematically corresponds to tumor regression of 119% TGI after 6 days of plasma exposure at this concentration. In the Ptch+/−p53−/− medulloblastoma allograft mice, the IC50 value is estimated to be 3.5 nM, consistent with the Ptch+/−p53+/− results. It is also able to cross the blood–brain barrier in rats within 4 hours post-dose.
References

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map